# FDA 483 - Comparative Biosciences, Inc - April 10, 2026

Source: https://www.keypedia.com/records/483/comparative-biosciences-inc/3fa0b32f-9cd9-4337-a404-c6f530a4dbd2

> FDA 483 for Comparative Biosciences, Inc on April 10, 2026. Product: other. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Comparative Biosciences, Inc
- Inspection Date: 2026-04-10
- Product Type: other
- Office Name: San Francisco District Office
- Summary: Comparative Biosciences, Inc. in Sunnyvale, CA, underwent a Good Laboratory Practice inspection that revealed a significant failure by the study director to ensure unforeseen circumstances affecting nonclinical laboratory study quality and integrity were noted and documented with corrective actions. This included instances of test article contamination in multiple studies and repeated freeze-thaw errors. The Quality Assurance Manager also signed compliance statements despite these undocumented issues, indicating serious deficiencies in GLP compliance and data integrity.

## Related Documents

- [483 - 2019-05-17](https://www.keypedia.com/records/483/comparative-biosciences-inc/a65edc9a-f357-40d5-80bb-3a06625345ec)
- [483 - 2024-07-30](https://www.keypedia.com/records/483/comparative-biosciences-inc/17ad7641-5177-4b8d-8995-fa0ea23668a8)

## Related Officers

- [Scott N. Lim](https://www.keypedia.com/people/scott-n-lim/d5e7745a-d804-48d1-8f3b-a94a8d4aed8a)

Company: https://www.keypedia.com/companies/comparative-biosciences-inc/c0722afa-cde7-48f7-a4d3-630d5c827079

Office: https://www.keypedia.com/offices/san-francisco-district-office/6f838e9c-aae1-4665-9c46-a51d43be02df